All AbMole products are for research use only, cannot be used for human consumption.
NSC 74859 (S3I-201) is a selective Stat3 inhibitor with an IC50 of 86 μM. NSC 74859 (S31-201) is effective in hepatocellular cancers with disrupted TGF-beta signaling.Both CD133 (+) Huh-7 cells and CD133 (-) Huh-7 cells are equally sensitive to NSC 74859 treatment and STAT3 inhibition, with an IC (50) of 100 muM.Furthermore, NSC 74859 (S31-201) treatment of Huh-7 xenografts in nude mice significantly retarded tumor growth, with an effective dose of only 5 mg/kg. Moreover, NSC 74859 (S31-201) inhibited tyrosine phosphorylation of STAT3 in HCC cells in vivo.*The compound is unstable in solutions, freshly prepared is recommended
 |
Source | Liver Int (2012). Figure 1. NSC 74859 |
| Method | MTT assay | |
| Cell Lines | Non-small cell | |
| Concentrations | 100 μM | |
| Incubation Time | 48 h | |
| Results | Cell viability of hepatoma cells treated with a combination of cetuximab and 100 μM of NSC 74859 decreased significantly, when compared with hepatoma cells treated with cetuximab alone (when the concentration of cetuximab >100 mg/ml, P < 0.0001 for all cell lines) |
| Cell Experiment | |
|---|---|
| Cell lines | NIH 3T3, NIH 3T3/v-Src, MDA-MB-453, MDA-MB-435, MDA-MB-231, or MDA-MB-468 cells line |
| Preparation method | Measurement of Apoptosis by Flow Cytometry. Proliferating cells were treated with or without S3I-201 for up to 48 h. In some cases, cells were first transfected with Stat3C, ST3-NT, or ST3-SH2 domain or mock-transfected for 24 h before treatment with compound for an additional 24-48 h. Cells were then detached and analyzed by annexin V binding (BD Biosciences, San Diego, CA) according to the manufacturer's protocol and flow cytometry to quantify the percent apoptosis. |
| Concentrations | 100 μ M |
| Incubation time | 48 h |
| Animal Experiment | |
|---|---|
| Animal models | Human breast (MDA-MB-231) tumor-bearing mice |
| Formulation | normal saline |
| Dosages | 5 mg/kg every 2 or every 3 days |
| Administration | i.v. |
| Molecular Weight | 365.36 |
| Formula | C16H15NO7S |
| CAS Number | 501919-59-1 |
| Solubility (25°C) | DMSO 80 mg/mL |
| Storage |
Powder -20°C 3 years ; 4°C 2 years In solvent -80°C 6 months ; -20°C 1 month |
| Related STAT Products |
|---|
| HP590
HP590 is an orally active, novel and potent STAT3 inhibitor (STAT3 luciferase activity: IC50=27.8 nM; ATP inhibition: IC50=24.7 nM). |
| 1-(4-Chloro-3-(trifluoromethyl)phenyl)-3-(4-(4-cyanophenoxy)phenyl)urea
STAT3-IN-7 is a Sorafenib analogue and potently inhibits the phosphorylation of STAT3. |
| HJC0123
HJC0123 is a novel STAT3 inhibitor that suppresses the fibrogenic properties of HSCs. HJC0123 reduced the phosphorylation, nuclear translocation, and transcriptional activity of STAT3. HJC0123 treatment resulted in the inhibition of HSCs proliferation at submicromolar concentrations. It decreased the expression of STAT3-regulated proteins, induced cell cycle arrest, promoted apoptosis and downregulated SOCS3. |
| ODZ10117
ODZ10117 is a small molecule inhibitor of STAT3. ODZ10117 inhibited migration and invasion and induced apoptotic cell death by targeting STAT3 in glioblastoma cells. |
| OPB-111077
OPB-111077 is a first-in-class, novel, oral inhibitor of STAT3 and mitochondrial oxidative phosphorylation (OXPHOS) with anticancer activity. OPB-111077 inhibits mitochondrial respiratory chain complex I, which leads to inhibition of energy production and activation of the AMPK-mTOR energy stress sensor pathway. |
All AbMole products are for research use only, cannot be used for human consumption or veterinary use. We do not provide products or services to individuals. Please comply with the intended use and do not use AbMole products for any other purpose.
Products are for research use only. Not for human use. We do not sell to patients.
© Copyright 2010-2024 AbMole BioScience. All Rights Reserved.
